Panacea Biotec hits 5 per cent upper circuit on successful dengue vaccine trial

The share price of the global generic, speciality pharmaceutical & vaccine maker, Panacea Biotec, hits 5 per cent upper circuit on BSE today during the afternoon session.

Panacea Biotec announced on Thursday about its successful completion of phase 1/11 study of its novel, Tetravalent recombinant chimeric Dengue candidate vaccine, DengiAll.

This type of vaccine contains weakened bacteria or viruses that trigger the immune response but do not cause any kind of disease.

According to World Health Organisation (WHO), Dengue represents one of the ten biggest global health threats, and this vaccine will provide an option to reduce the impact of dengue fever in endemic regions.

Panacea Biotec is a biotechnology company that focusses on the development, discovery, and commercialisation of prescription medicines.

At 3.11 pm today, the share of Panacea Biotec was trading at Rs 196.80 on BSE, up by 4.99 per cent and has given 88.53 per cent returns over the last 6 months and 34.75 per cent within 12 months. On a YTD basis, the stock has gained by 50.91 per cent.